Literature DB >> 8703651

Patterns of drug treatment of schizophrenic patients in Estonia, Spain and Sweden.

R A Kiivet1, A Llerena, M L Dahl, L Rootslane, J Sánchez Vega, T Eklundh, F Sjöqvist.   

Abstract

1. Patterns of drug treatment and the use of polypharmacy in schizophrenic in-patients were compared and evaluated in the University Teaching Hospitals of Psychiatry in Badajoz, Spain, Huddinge, Sweden, and Tartu, Estonia. 2. The medical records of up to 100 consecutively admitted patients were retrospectively reviewed using a standardized data form. 3. The male patients were significantly younger than females in all study locations, but there were no age differences between the locations. The length of stay was equal for the two series in the same hospital, but considerably longer in Tartu than in Badajoz and Huddinge. 4. The neuroleptic drugs used most commonly in Badajoz and Tartu were similar in prescription frequency and in the doses prescribed, but different from those used in Huddinge. Haloperidol was the most frequently prescribed neuroleptic in Badajoz and Tartu, accounting for one third of all neuroleptic prescriptions. In Huddinge the choice of neuroleptics was more evenly spread over several compounds. Intramuscular injections other than depot preparations were commonly used in Tartu and Badajoz, but not in Huddinge. 5. At least two neuroleptics were prescribed simultaneously on 73% of treatment days in Badajoz and 46% in both Huddinge and Tartu. The average cumulative daily doses of concomitant multiple neuroleptic treatment, expressed in chlorpromazine equivalents, were lower in Huddinge than in the other study locations and higher for male patients in Badajoz and Tartu. 6. Anticholinergics were used together with neuroleptics in 42% of treatment days in Badajoz and 30% in Huddinge as compared with 75% in Tartu. The use of anticholinergics increased in parallel to the increase in the number and the cumulative dose of concomitant neuroleptics in all study locations. 7. About 15% of patients in Badajoz and Tartu, but only 1% in Huddinge, received concomitant treatment with antidepressant drugs. The simultaneous use of antidepressants and benzodiazepines was inversely related to the number and the cumulative dose of neuroleptics in Badajoz and Tartu. In contrast, the cumulative dose and number of neuroleptics were greater, when additional benzodiazepines were prescribed in Huddinge. 8. The study in schizophrenic in-patients revealed that polypharmacy with concomitant multiple neuroleptics, additional anticholinergics and other psychotropics is an international phenomenon.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8703651      PMCID: PMC1365193          DOI: 10.1111/j.1365-2125.1995.tb05791.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  24 in total

1.  Patterns of psychotropic drug use for schizophrenia.

Authors:  E Laska; E Varga; J Wanderling; G Simpson; G W Logemann; B K Shah
Journal:  Dis Nerv Syst       Date:  1973 Aug-Sep

2.  Dissimilar dosing with high-potency and low-potency neuroleptics.

Authors:  R J Baldessarini; B Katz; P Cotton
Journal:  Am J Psychiatry       Date:  1984-06       Impact factor: 18.112

3.  What is the best maintenance dose of neuroleptics in schizophrenia?

Authors:  R J Baldessarini; J M Davis
Journal:  Psychiatry Res       Date:  1980-10       Impact factor: 3.222

4.  Clinical use of the antipsychotics.

Authors:  K A Kessler; J P Waletzky
Journal:  Am J Psychiatry       Date:  1981-02       Impact factor: 18.112

Review 5.  Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses.

Authors:  R J Baldessarini; B M Cohen; M H Teicher
Journal:  Arch Gen Psychiatry       Date:  1988-01

6.  Pharmacotherapy of chronic hospitalized schizophrenics: prescription practices.

Authors:  W H Wilson; T A Ban; W Guy
Journal:  Neuropsychobiology       Date:  1985       Impact factor: 2.328

7.  Therapeutic traditions in Northern Ireland, Norway and Sweden: I. Diabetes. WHO Drug Utilization Research Group (DURG).

Authors:  K Griffiths; D G McDevitt; M Andrew; I Baksaas; A Helgeland; J Jervell; P K Lunde; K Oydvin; I Agenäs; U Bergman
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

8.  Prescribing for the long-term mentally ill. A study of treatment practices.

Authors:  F Holloway
Journal:  Br J Psychiatry       Date:  1988-04       Impact factor: 9.319

9.  Concurrent use of more than one major psychotropic drug (polypsychopharmacy) in out-patients--a prescription database study.

Authors:  J U Rosholm; J Hallas; L F Gram
Journal:  Br J Clin Pharmacol       Date:  1994-06       Impact factor: 4.335

10.  Therapeutic traditions in Northern Ireland, Norway and Sweden: II. Hypertension. WHO Drug Utilization Research Group (DURG).

Authors:  K Griffiths; D G McDevitt; M Andrew; I Baksaas; A Helgeland; J Jervell; P K Lunde; K Oydvin; I Agenäs; U Bergman
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

View more
  13 in total

1.  Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia.

Authors:  Kang Sim; Alex Su; Senta Fujii; Shu-Yu Yang; Mian-Yoon Chong; Gabor S Ungvari; Tianmei Si; Eun K Chung; Hin-Yeung Tsang; Yiong H Chan; Stephan Heckers; Naotaka Shinfuku; Chay H Tan
Journal:  Br J Clin Pharmacol       Date:  2004-08       Impact factor: 4.335

Review 2.  Drug development and use in the elderly: search for the right dose and dosing regimen (Parts I and II).

Authors:  Rashmi R Shah
Journal:  Br J Clin Pharmacol       Date:  2004-11       Impact factor: 4.335

Review 3.  Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009.

Authors:  Juan A Gallego; John Bonetti; Jianping Zhang; John M Kane; Christoph U Correll
Journal:  Schizophr Res       Date:  2012-04-24       Impact factor: 4.939

4.  Safety and tolerability of antipsychotic polypharmacy.

Authors:  Juan A Gallego; Jimmi Nielsen; Marc De Hert; John M Kane; Christoph U Correll
Journal:  Expert Opin Drug Saf       Date:  2012-05-08       Impact factor: 4.250

Review 5.  Patient compliance with drug therapy in schizophrenia. Economic and clinical issues.

Authors:  E Lindström; K Bingefors
Journal:  Pharmacoeconomics       Date:  2000-08       Impact factor: 4.981

6.  Patterns of neuroleptic drug prescription: a national cross-sectional survey of a random sample of French psychiatrists.

Authors:  A Fourrier; I Gasquet; M P Allicar; M Bouhassira; J P Lépine; B Bégaud
Journal:  Br J Clin Pharmacol       Date:  2000-01       Impact factor: 4.335

Review 7.  Antipsychotic polypharmacy in schizophrenia: benefits and risks.

Authors:  Thomas R E Barnes; Carol Paton
Journal:  CNS Drugs       Date:  2011-05       Impact factor: 5.749

Review 8.  Ziprasidone in the management of schizophrenia : the QT interval issue in context.

Authors:  David Taylor
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 9.  Antipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a long-standing clinical practice.

Authors:  Christoph U Correll; Juan A Gallego
Journal:  Psychiatr Clin North Am       Date:  2012-07-24

10.  Polypharmacy with antipsychotic drugs in patients with schizophrenia: trends in multiple health care systems.

Authors:  FangFang Sun; Eileen M Stock; Laurel A Copeland; John E Zeber; Brian K Ahmedani; Sandra B Morissette
Journal:  Am J Health Syst Pharm       Date:  2014-05-01       Impact factor: 2.637

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.